Indemnity clause: Serum Institute of India knocks on govt door again

Amid adverse events following vaccination coming from across the country, Pune-based vaccine maker Serum Institute of India (SII) again raised the issue of indemnity in a meeting with the health ministry this week, said someone close to the development.

SII did not wish to comment on the matter. While there are reports of adverse events, no causal link to the vaccine has been established. SII Chief Executive Officer Adar Poonawalla earlier indicated legal indemnity was required to ensure that the vaccination drive could be completed smoothly.

In an interview with Business Standard, Poonawalla, who is also president of the Indian Vaccine Manufacturers